Biogen’s head of R&D Michael Ehlers (pictured above) is leaving the company after three years, and some high-profile failures in its late-stage pipeline.
Just a few days after calling time on its Eisai-partnered Alzheimer’s drug elenbecestat, Biogen has another pipeline casualty – this time its idiopathic pulmonary fibrosis (IPF) therapy STX-100.
One of the last major, late-stage attempt at stopping Alzheimer’s disease (AD) using a BACE inhibitor has ended up on the trash pile with so many others.
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that two oral and 13 poster presentations about its Alzheimer's Disease (AD), dementia pipeline will be presented at the 2019 Alzheimer's Association International Conference (AAIC), July 14-18, in Los Angeles.
Eisai Co., Ltd. announced that a total of seven presentations highlighting the latest data on its Alzheimer's disease/dementia pipeline, including anti-amyloid beta (Abeta) protofibril antibody BAN2401 and oral beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat will be given at the 14th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD) from March 26 to 31 in Lisbon, Portugal.
WOODCLIFF LAKE, N.J., March 22, 2019 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that seven poster presentations from its Alzheimer's disease/dementia pipeline will be highlighted at the 14th International Conference on Alzheimer's & Parkinson's Diseases (AD/PD) on March 26-31 in Lisbon, Portugal.
Eisai starts phase 3 trials for second Alzheimer`s drug after first`s failure
BEIJING and NEW HAVEN, Conn., Aug. 31, 2018 /PRNewswire/ -- XingImaging LLC, a radiopharmaceutical production and positron emission tomography (PET) acquisition company operating in Mainland China announced today that they are using PET Imaging to support multi-center Alzheimer's disease (AD) clinical trials requiring PET for eligibility and disease evaluation.
A phase 2 Alzheimer’s trial—once nearly consigned to the heap of disappointing attempts against the disease—has re-emerged with new positive results, showing that an anti-amyloid beta protofibril antibody can slow clinical symptom decline, as well as reduce the accumulation of plaque in the brain.